Virulence Factors Associated With *Escherichia coli* Bacteremia and Urinary Tract Infection

Bongyoung Kim, M.D., Ph.D.¹, Jin-Hong Kim, M.D.², and Yangsoon Lee, M.D., Ph.D.²

Departments of ¹Internal Medicine and ²Laboratory Medicine, Hanyang University College of Medicine, Seoul, Korea

**Background:** Extraintestinal pathogenic *Escherichia coli* (ExPEC) causes various infections, including urinary tract infection (UTI), sepsis, and neonatal meningitis. ExPEC strains have virulence factors (VFs) that facilitate infection by allowing bacterial cells to migrate into and multiply within the host. We compared the microbiological characteristics of ExPEC isolates from blood and urine specimens from UTI patients.

**Methods:** We conducted a single-center, prospective study in an 855-bed tertiary-care hospital in Korea. We consecutively recruited 80 hospitalized UTI patients with *E. coli* isolates, which were isolated from blood and/or urine, and urine alone between March 2019 and May 2020. We evaluated the 80 *E. coli* isolates for the presence of bacterial genes encoding the sequence types (STs), antimicrobial resistance, and VFs using whole-genome sequencing (WGS).

**Results:** We found no significant differences in STs, antimicrobial resistance patterns, or VFs between isolates from blood and urine specimens. ST131, a pandemic multidrug-resistant clone present in both blood and urine, was the most frequent ST (N=19/80, 24%), and ST131 isolates carried more virulence genes, especially *tsh* and *espC*, than non-ST131 isolates. The virulence scores of the ST131 group and the ST69, ST95, and ST1193 groups differed significantly (*P*<0.05).

**Conclusions:** We found no STs and VFs associated with bacteremia in WGS data of *E. coli* isolates from UTI patients. ST131 was the most frequent ST among UTI causing isolates and carried more VF genes than non-ST131 isolates.

**Key Words:** *Escherichia coli*, ST131, Urinary tract infection, Whole-genome sequencing, *tsh*, Virulence factors

---

**INTRODUCTION**

Extraintestinal pathogenic *Escherichia coli* (ExPEC) causes various infections, including urinary tract infection (UTI), sepsis, and neonatal meningitis [1, 2]. The mechanisms underlying ExPEC transmission and the selection of resistant clones are poorly understood.

Among multidrug-resistant ExPEC strains, the most frequent sequence type (ST) is ST131, which is globally disseminated and resistant to multiple antibiotics [3, 4]. Recently, ST1193, which is resistant to fluoroquinolones, has spread rapidly [4]. ExPEC strains have virulence factors (VFs), including adhesion molecules, iron acquisition systems, invasion proteins, and toxins, which facilitate infection by allowing bacterial cells to migrate into and multiply within the host. Several ExPEC VF genes, including *pap*, *vat*, *kpsMII*, *ibeA*, and *clbB/N*, are significantly associated with the dissemination of ExPEC isolates [5, 6]. The yersiniabactin siderophore receptor encoded by *fyuA* is involved in the efficient uptake of iron from the bloodstream and invasion of the bloodstream from the urinary tract [7]. Pneumonia-spe-
cific E. coli isolates carry higher proportions of the VF genes sfa/ foc, papGIII, hlyC, cnf1, and iroN than bacteremia isolates [8]. The gene cnf1 encodes cytotoxic necrotizing factor 1, a toxin associated with sepsis severity, whereas the presence of fyuA is associated with mortality. Further, the presence of P fimbriae is associated with improved bacterial survival [9, 10]. The presence of hek/hra may predict clinical outcomes, as one study showed an association between the presence of these genes and mortality in newborns [11].

ExPEC strains involved in UTIs are believed to express a diverse repertoire of VFs to colonize and infect the urinary tract in an ascending manner [1]. However, the role of VFs in the pathogenesis and clinical outcomes of E. coli bacteremia remains to be investigated. We hypothesized that some VFs of ExPEC are involved in bacterial movement into the bloodstream in UTI patients, resulting in urosepsis. Therefore, we compared the repertoire of STs and VF genes between isolates from urine and blood from UTI patients using whole-genome sequencing (WGS) analysis.

**MATERIALS AND METHODS**

**Patients and definitions**

We conducted a prospective study in the 855-bed Hanyang University Hospital, Seoul, Korea. We consecutively recruited hospitalized UTI patients with E. coli isolates from blood and/or urine (N=40) and with E. coli isolates from urine alone (N=40), between March 2019 and May 2020. Patients with UTI were defined as those who met all of the following criteria: (i) fever (body temperature ≥37.8°C), (ii) pyuria (≥5–9 white blood cells per high-power field), (iii) clinical symptoms or signs relevant to UTI as judged by an infectious disease specialist, and (iv) absence of other medical conditions that can cause fever or pyuria. We collected clinical data, including demographic data (age and sex), time lag between fever or UTI symptoms (dysuria, frequency, urgency, or nocturia) and bacterial culture sampling, history of antibiotic use prior to bacterial culture sampling, and existence of underlying urinary tract abnormalities. Antibiotic regimens were considered concordant, if they included at least one antibiotic active against the causative or-

**Table 1. Clinical factors possibly influencing the culture results of blood and urine specimens**

| Clinical factor                                      | Blood (N=40) | Urine (N=40) | P       |
|------------------------------------------------------|--------------|--------------|---------|
| Age, median (IQR)                                    | 72.5 (59–81) | 70 (54.5–78.5) | 0.473   |
| Male sex, N (%)                                      | 4 (10.0)     | 2 (5.0)      | 0.675   |
| Time lag between fever or UTI symptom onset and bacterial culture sampling, days, median (IQR) | 2 (1–3.75)   | 1 (0–4)      | 0.382   |
| History of antibiotic use within three days prior to bacterial culture sampling | 8/39 (20.5)  | 7 (17.5)     | 0.733   |
| Antimicrobial use concordant with the antimicrobial susceptibility of the causative organisms | 3/39 (7.7)   | 1 (2.5)      | 0.359   |
| Existence of any underlying urinary tract abnormalities | 18 (45.0)    | 17 (42.5)    | 0.822   |
| Benign prostatic hypertrophy among male patients     | 1/4 (25.0)   | 2/2 (100)    | 0.400   |
| Neurogenic bladder                                   | 1 (2.5)      | 2 (5.0)      | 1.000   |
| Urolithiasis                                          | 12 (30.0)    | 5 (12.5)     | 0.056   |
| Urinary retention                                    | 0 (0)        | 1 (2.5)      | 1.000   |
| Vesicoureteral reflux                                 | 0 (0)        | 0 (0)        | -       |
| Bladder diverticulum                                  | 0 (0)        | 1 (2.5)      | 1.000   |
| Prolapse of vagina among female patients              | 0 (0)        | 0 (0)        | -       |
| Intubated urinary tract at the time of culture sampling | 5 (12.5)    | 9 (22.5)     | 0.239   |
| Intermittent catheterization                         | 0 (0)        | 2 (5.0)      | 0.494   |
| History of urinary catheterization during one month prior to inclusion | 4 (10.0)    | 3 (7.5)      | 1.000   |
| Polycystic kidney                                     | 0 (0)        | 0 (0)        | -       |
| Kidney tumor                                          | 0 (0)        | 1 (2.5)      | 1.000   |
| Urinary tract surgery during three months prior to inclusion | 2 (5.0)    | 1 (2.5)      | 1.000   |
| Surgically reconstructed bladder                      | 0 (0)        | 0 (0)        | -       |

Abbreviations: IQR, interquartile range; UTI, urinary tract infection.
organisms based on in vitro susceptibility testing. The clinical factors that may have influenced the culture results of blood and urine specimens, are listed in Table 1. No significant differences were found in these clinical factors. This study was approved by the Hanyang University Hospital Institutional Review Board, with waiver of informed consent (IRB N 201905054).

Bacterial culture and antimicrobial susceptibility testing
Blood culture bottles were incubated in the BACT/ALERT VIRTUO System (bioMérieux, Marcy l’Étoile, France). Urine specimens were inoculated on blood agar and MacConkey agar plates, and the plates were incubated at 35°C for 24 hours. Bacterial species were identified by matrix-assisted laser desorption/ionization (MALDI) time-of-flight mass spectrometry using the MALDI Biotyper system and related software (version 2.3, Bruker Daltonics, Bremen, Germany). Antimicrobial susceptibility was tested using the MicroScan Walkaway system (Beckman Coulter, Brea, CA, USA), and the results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines, with intermediate isolates designated as resistant [12]. All isolates were maintained in 20% skim milk at –80°C.

WGS analysis
Bacterial isolates cultured on MacConkey agar plates were sent to Macrogen (Seoul, Korea) for WGS that was performed using the Illumina system (Illumina, Inc., San Diego, CA, USA). De novo assembly and assembly validation were performed for all 80 isolates. WGS data were analyzed using the Center for Genomic Epidemiology website (http://www.genomicepidemiology.org/), and multilocus ST (MLST), serotype, fimH type, antimicrobial resistance gene repertoire, and VF repertoire were determined. The presence of several virulence traits was determined using the VF analyzer pipeline and VF database (http://www.mgc.ac.cn/VFs/) [13]. Virulence scores were calculated as the sum of VFs present in each isolate [5].

Statistical analysis
The chi-square test (Fisher’s exact test) was used to compare clinical factors, ST, antimicrobial resistance rates between blood and urine groups, and the Kruskal–Wallis test was used to compare virulence scores according to ST. Data was analyzed using SPSS 26 (SAS Institute Inc., Cary, NC, USA), and P<0.05 was considered statistically significant.

RESULTS

Molecular epidemiological characteristics
The MLST results revealed a diverse population comprising 18 STs (Table 2). The most frequent STs were ST131 (N=19, 24%), ST95 (N=16, 20%), ST69 (N=11, 14%), and ST1193 (N=9, 11%). We detected five ST73 isolates and two ST127 isolates. There were no significant differences in ST frequencies between the blood and urine specimens. ST12 was more frequently found in urine specimens than in blood specimens (P=0.04), but only four isolates were obtained.

FimH typing revealed that fimH27 isolates were the most frequent (N=22, 28%), followed by fimH30 isolates (N=14, 18%). We also determined fimH-OH serotype clonal groups among the ST isolates. Among the 19 ST131 isolates, the ST131-fimH30-O25:H4 group was predominant (N=14, 74%). Among the 16 ST95 isolates, ST95-fimH27 isolates were the most frequent (N=11, 69%). All nine ST1193 isolates were fimH64, whereas this type was not found among non-ST1193 isolates.

| Table 2. Number of isolates (%) according to MLST in blood and urine specimens |
|-----------------|---------|---------|-----|
| ST-fimH-serotype | Blood (N=40) | Urine (N=40) | P   |
| ST131            | 8 (20)  | 11 (28)  | 0.431 |
| ST131-fimH30-025:H4 | 6 (15)  | 8 (0.556) | 0.556 |
| ST131-fimH41-016:H5 | 2 (5)   | 2 (1.000) | 1.000 |
| ST131-fimH99-025:H4 | 0 (0)   | 1 (0.314) | 0.314 |
| ST95             | 9 (23)  | 7 (18)   | 0.576 |
| ST95-fimH27-02:H4 | 6 (15)  | 3 (0.288) | 0.288 |
| ST95-fimH27-02:H7 | 1 (3)   | 1 (1.000) | 1.000 |
| ST95-fimH41      | 2 (5)   | 2 (1.000) | 1.000 |
| ST95-fimH54      | 0 (0)   | 1 (0.314) | 0.314 |
| ST69-fimH27      | 8 (20)  | 3 (8)    | 0.105 |
| ST1193           | 4 (10)  | 5 (13)   | 0.723 |
| ST1193-fimH64-075:H5 | 3 (8)   | 4 (0.692) | 0.692 |
| ST1193-fimH64-018:H5 | 1 (3)   | 1 (1.000) | 1.000 |
| ST73             | 3 (8)   | 2 (5)    | 0.644 |
| ST12             | 0 (0)   | 4 (10)   | 0.040 |
| ST38             | 1 (3)   | 2 (5)    | 0.556 |
| ST127            | 0 (0)   | 2 (5)    | 0.152 |
| ST357            | 1 (3)   | 1 (3)    | 1.000 |
| Others*          | 6 (15)  | 3 (8)    | 0.288 |

*Nine isolates belonging to ST10, ST14, ST70, ST372, ST394, ST421, ST457, ST998, and ST2613

Abbreviations: ST, sequence type; MLST, multilocus sequence type.
Antimicrobial resistance patterns and antimicrobial resistance genes

The ampicillin and ampicillin/sulbactam resistance rates were 72.5% and 40.0%, respectively, for blood isolates and 75.0% and 45.0%, respectively, for urine isolates. In addition, 20.0% of blood isolates and 27.5% of urine isolates were extended spectrum \(\beta\)-lactamase (ESBL) producers. We found no significant differences in antimicrobial resistance rates between blood and urine isolates (Table 3). However, ST131 and ST1193 isolates showed higher resistance rates than the other isolates. The cefotaxime, ceftazidime, aztreonam, and cefepime resistance rates of ST131 isolates (78.9%) were higher than those of non-ST131 isolates (0%–12.0%). Among the 19 ST131 isolates, 15 carried ESBL-associated genes including CTX-M-15, CTX-M-27, CTX-M-55, and CTX-M-14. CTX-M-14 genes were detected in ST95, ST38, and ST457, and the \(DHA-1\) gene was detected in one ST12 isolate (Table 4). Of the 80 \(E. coli\) isolates, 27 (33.8%) were resistant to fluoroquinolone. Among them, the most prevalent clonal group was ST131-\(fimH\)30, followed by ST1193-\(fimH\)64. All ST1193 isolates were resistant to ciprofloxacin. Quinolone

| Antimicrobial agent | ST (N of isolates) | Specimen type (N isolates) |
|---------------------|--------------------|--------------------------|
|                     | ST131 (19)         | ST95 (16) | ST69 (11) | ST1193 (9) | Others (25) | Blood (40) | Urine (40) |
| Ampicillin          | 89.5               | 31.3     | 81.8      | 88.9      | 80.0        | 72.5       | 75.0       |
| Piperacillin        | 84.2               | 31.3     | 81.8      | 88.9      | 72.0        | 72.5       | 67.5       |
| Cefoxitin           | 0                  | 0        | 0         | 11.1      | 4.0         | 0          | 5.0        |
| Ceftazidime         | 78.9               | 6.3      | 0         | 0         | 12.0        | 20.0       | 27.5       |
| Cefotaxime          | 78.9               | 6.3      | 0         | 11.1      | 12.0        | 20.0       | 30.0       |
| Cefuroxime          | 78.9               | 6.3      | 9.1       | 11.1      | 12.0        | 22.5       | 30.0       |
| Aztreonam           | 78.9               | 6.3      | 0         | 11.1      | 12.0        | 22.5       | 27.5       |
| Cefepime            | 78.9               | 6.3      | 0.0       | 0         | 12.0        | 20.0       | 27.5       |
| Ampicillin/sulbactam| 31.6               | 12.5     | 63.6      | 55.6      | 56.0        | 40.0       | 45.0       |
| Amoxicillin/clavulanate | 26.3           | 0.0      | 9.1       | 11.1      | 12.0        | 2.5        | 22.5       |
| Piperacillin/tazobactam | 5.3          | 0        | 9.1       | 0         | -           | 2.5        | 2.5        |
| Doripenem           | 0                  | 0        | 0         | 0         | 0           | 0          | 0          |
| Ertapenem           | 0                  | 0        | 0         | 0         | 0           | 0          | 0          |
| Meropenem           | 0                  | 0        | 0         | 0         | 0           | 0          | 0          |
| Imipenem            | 0                  | 0        | 0         | 0         | 0           | 0          | 0          |
| Amikacin            | 0                  | 0        | 0         | 0         | 0           | 0          | 0          |
| Gentamicin          | 47.4               | 0        | 27.3      | 22.2      | 16.0        | 25.0       | 20.0       |
| Tobramycin          | 52.6               | 0.0      | 27.3      | 22.2      | 8.0         | 22.5       | 20.0       |
| Trimethoprim/sulfamethoxazole | 52.6         | 12.5     | 45.5      | 33.3      | 40.0        | 42.5       | 32.5       |
| Ciprofloxacin       | 73.7               | 6.3      | 9.1       | 100.0     | 8.0         | 30.0       | 37.5       |
| Levofloxacin        | 73.7               | 6.3      | 0         | 88.9      | 8.0         | 22.5       | 37.5       |
| Chloramphenicol     | 0                  | 6.3      | 0         | 0.0       | 8.0         | 2.5        | 5.0        |
| Fosfomycin          | 0                  | 0        | 0         | 0         | 0           | 0          | 0          |
| Tetracycline        | 57.9               | 12.5     | 18.2      | 33.3      | 32.0        | 30.0       | 35.0       |
| Minocycline         | 0                  | 0        | 0         | 11.1      | 16.0        | 5.0        | 7.5        |
| Tigecycline         | 0                  | 0        | 0         | 0         | 0           | 0          | 0          |
| Colistin            | 0                  | 0        | 0         | 0         | 0           | 0          | 0          |
| ESBL positive       | 78.9               | 6.3      | 0         | 0         | 12.0        | 20.0       | 27.5       |

Resistance rates >50% are indicated in bold. Abbreviations: ST, sequence type; ESBL, extended-spectrum \(\beta\)-lactamase.

Table 3. Antimicrobial resistance rates (%) according to ST and specimen type
resistance analysis revealed quinolone resistance-determining region (QRDR) point variants in *gyrA*, *parC*, and *parE*. All 27 fluoroquinolone-resistant isolates carried the variations S83L and D87N or D87Y in *gyrA*; S80I and/or E84V in *parC* were detected in 24/27 (89%) isolates, and I529L, L416F, and S458A in *parE* were detected in 23/27 (78%) isolates.

**Prevalence of VFs**

Reference strains were uropathogenic *E. coli* (UPEC) strains (*E. coli* CFT073, *E. coli* O25b:H4-ST131, and *E. coli* VR50), adherent and invasive *E. coli* strains (*E. coli* UM146 and *E. coli* O83:H1 strain NRG 857C), neonatal meningitis *E. coli* (NMEC) strains (*E. coli* O7:K1 strain CE10 and *E. coli* O45:K1:H7), and an enterohemorrhagic *E. coli* strain (*E. coli* O157:H7 strain EDL933). In total, 56 VFs were examined and categorized as adhesion molecules, autotransporter systems, invasion proteins, or toxins (Table 5). All isolates carried *E. coli* common pilus, hemorrhagic *E. coli* pilus, and *EaeH*. The frequencies of individual VFs according to ST ranged from 91%–100% for type I fimbriae and 64%–100% for P fimbriae. F1C or S fimbriae were not detected in prevalent isolates, such as ST131, ST95, ST69, and ST1193. Among VFs associated with autotransporter systems, the temperature-sensitive hemagglutinin gene (*tsh*) was detected in all ST131 and ST1193 isolates, 6% of ST95 isolates, and 0% of ST69 isolates. Among invasion VFs, *ibeA*, associated with neonatal meningitis, was detected in only four (5%) isolates, including ST357, ST372, and ST998 isolates. Iron uptake systems, such as the sitABCD pump and chuA system, were detected in nearly all isolates (98%) (Table 5). Yersiniabactin, aerobactin, and salmochelin siderophores, which are indirect iron uptake systems, were detected in 99%, 63%, and 29% of the isolates, respectively. In ST131 and ST1193 isolates, yersiniabactin and aerobactin siderophores were more frequent than salmochelin siderophores. In contrast, salmochelin siderophores were more frequent (68%) in other isolates than ST131 (5%) and ST1193 (0%) isolates. Several toxin genes were detected in UTI-associated isolates. The *hlyE* gene was detected in all isolates. The *usp* and *senB* genes were predominant in 78% and 55%, respectively, of the isolates. The alpha-hemolysin genes, *hlyA*, *hlyB*, and *hlyD*, were detected in 35% of the isolates. These toxin genes were more frequent in the ST131 group (53%) than in the non-ST131 group (30%), but the difference was not significant (P=0.07). The *cnf1* gene was more frequent in the ST131 group (53%) than in the non-ST131 groups (20%) (P<0.05).

---

**Table 4. Antimicrobial resistance mechanisms of ESBL-producing and fluoroquinolone-resistant isolates according to ST-*fimH*-serotype**

| ST-*fimH*-serotype | ESBL gene | QRDR variation in *gyrA* | *parC* | *parE* | N isolates |
|---------------------|-----------|--------------------------|--------|--------|-----------|
| ST131-*fimH*30-025:H4 | CTX-M-15 | S83L, D87N | S80I, E84V | I529L | 8 |
| ST131-*fimH*14-27:H4 | CTX-M-14, 27 | S83L, D87N | S80I, E84V | I529L | 2 |
| ST131-*fimH*99-025:H4 | CTX-M-55 | S83L, D87N | S80I, E84V | I529L | 2 |
| ST95-*fimH*41-01:H7 | CTX-M-27 | S83L, D87N | - | I529L | 1 |
| ST95-*fimH*27-02:H4 | - | S83L, D87Y | S80R | - | 1 |
| ST38-*fimH*19-086:H18 | CTX-M-14 | S83L, D87Y | S80I | S458A | 1 |
| ST38-*fimH*65-025:H15 | - | S83L, D87N | S80I, E84V | - | 1 |
| ST457-*fimH*145-011:H25 | CTX-M-14 | - | - | - | 1 |
| ST12-*fimH*27-04:H5 | DHA-1 | - | - | - | 1 |
| ST119-*fimH*64-075:H5 | - | S83L, D87N | S80I | L416F | 5 |
| ST119-*fimH*145-011:H25 | - | S83L, D87N | - | - | 2 |
| ST69-*fimH*17-01:H18 | - | S83L, D87N | S80I | L416F | 1 |

Abbreviations: ESBL, extended-spectrum β-lactamase; QRDR, quinolone resistance-determining region; -, not detected; ST: sequence type.
Table 5. Proportions (%) of VFs according to ST and specimen type

| VF                                      | VF gene | ST (N isolates) | Specimen type (N isolates) | Total (80) |
|-----------------------------------------|---------|-----------------|----------------------------|------------|
|                                         |         | ST131 (19)      | ST95 (16)                  | ST69 (11)  | ST1193 (9) | Others (25) | Blood (40) | Urine (40) |     |
| Adherence                               |         |                 |                            |            |            |            |            |            |     |
| *E. coli* common pilus                   | ecp     | 100             | 100                        | 100        | 100        | 100        | 100        | 100        | 100        |
| Hemorrhagic *E. coli* pilus              | hcp     | 100             | 100                        | 100        | 100        | 100        | 100        | 100        | 100        |
| EaeH                                    | eaeH    | 100             | 100                        | 100        | 100        | 100        | 100        | 100        | 100        |
| Type I fimbriae                         | fim     | 100             | 100                        | 91         | 100        | 100        | 100        | 100        | 100        |
| P fimbriae                              | pap     | 95              | 94                         | 64         | 100        | 80         | 85         | 88         | 86         |
| F1C fimbriae                            | foc     | 0               | 0                          | 0          | 0          | 52         | 13         | 20         | 16         |
| Afimbrial adhesin AFA-I                 | afa, draP | 16              | 6                          | 9           | 0          | 32         | 18         | 15         | 16         |
| S fimbriae                              | sfa     | 0               | 0                          | 0           | 0          | 40         | 10         | 15         | 13         |
| Aadf/fimbiae                            | aaf     | 21              | 0                          | 9           | 0          | 8          | 15         | 3          | 9          |
| *E. coli* laminin-binding fimbriae      | elf     | 0               | 0                          | 0           | 0          | 24         | 8          | 8          | 8          |
| CFIA fimbriae                           | cfa     | 0               | 0                          | 0           | 0          | 16         | 5          | 5          | 5          |
| Aadf/fimbiae                            | agg3    | 0               | 0                          | 0           | 0          | 4          | 0          | 3          | 1          |
| K88 fimbriae                            | fae     | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| Curli fibers                            | cgs, csg | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| EtpA                                    | etpA    | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| Dispersin                               | aap     | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| Intimin                                 | eae     | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| Porcine attaching-effacing associated protein | paa | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| ToxB                                    | toxB    | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| Autotransporters                        |         |                 |                            |            |            |            |            |            |     |
| UpaG adhesin, trimeric AT               | upaG    | 95              | 100                        | 100        | 100        | 88         | 95         | 95         | 95         |
| EhaB, AIDA-I type                       | ehaB    | 89              | 88                         | 100        | 100        | 88         | 93         | 90         | 91         |
| Antigen 43, AIDA-I type                 | agr43   | 89              | 69                         | 45         | 100        | 60         | 70         | 73         | 71         |
| Temperature-sensitive hemagglutinin     | tsh     | 100             | 6                          | 0          | 100        | 32         | 40         | 53         | 46         |
| Sat                                     | sat     | 79              | 0                          | 55         | 89         | 32         | 55         | 38         | 46         |
| Vacciulating autotransporter gene       | vat     | 0               | 81                         | 9           | 44         | 68         | 45         | 43         | 44         |
| Cag, AIDA-I type                        | cag     | 63              | 38                         | 18         | 0          | 44         | 35         | 43         | 39         |
| EspC, SPATE                             | espC    | 100             | 6                          | 0           | 0          | 16         | 25         | 35         | 30         |
| Enteraggregative immunoglobulin repeat protein | air/aeAX | 0       | 0                          | 100        | 0          | 24         | 28         | 15         | 21         |
| Contact-dependent growth inhibition system | cdi | 11              | 0                          | 0           | 0          | 48         | 10         | 25         | 18         |
| UpaH, AIDA-I type                       | upaH    | 0               | 0                          | 9           | 33         | 12         | 10         | 8          | 9          |
| Pic                                     | pic     | 0               | 0                          | 0           | 0          | 24         | 13         | 3          | 8          |
| AIDA-I                                  | aida    | 11              | 0                          | 0           | 0          | 0          | 5          | 0          | 3          |
| EhaA, AIDA-I type                       | ehaA    | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| EspI, SPATE                             | espl    | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| Pet, SPATE                              | pet     | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| AIDA-I type                             | tibA    | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| AstA, AIDA-I type                       | aatA    | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |
| EspP                                    | espl    | 0               | 0                          | 0           | 0          | 0          | 0          | 0          | 0          |

(Continued to the next page)
Table 5. Continued

| VF                                      | VF gene | ST (N isolates) | Specimen type (N isolates) | Total (80) |
|-----------------------------------------|---------|-----------------|----------------------------|------------|
|                                         |         | ST131 (19)      | ST95 (16)                  | ST69 (11)  |
|                                         |         |                 | ST1193 (9)                 | Others (25) |
|                                         |         | Blood (40)      | Urine (40)                 | Total (80) |
| Invasion                                |         |                 |                            |            |
| Invasion of brain endothelial cells     |ibeABC   | 0 0 0 0 16      | 5 5 5                      |            |
| Tia/Hek                                 |tia      | 53 88 18 0 68   | 53 55 54                  |            |
| Iron uptake                             |         |                 |                            |            |
| Iron/manganese transport                |sitA     | 100 100 100 100 92 | 98 98 98                  |            |
| Heme uptake                             |chuA     | 100 100 91 100 96 | 98 98 98                   |            |
| Yersiniabactin siderophore              |fyuA     | 100 100 91 100 96 | 98 100 99                 |            |
| Aerobactin siderophore                  |iucC     | 74 44 73 89 52  | 73 53 63                   |            |
| Iron-regulated element                  |iraA     | 5 88 18 0 44    | 40 30 35                   |            |
| Salmochelin siderophore                 |iroN     | 5 13 27 0 68    | 28 30 29                   |            |
| Toxins                                  |         |                 |                            |            |
| Hemolysin/cytolysin A                   |hlyE/chyA| 100 100 100 100 100 | 100 100 100 100 |            |
| Colicin-like Usp                        |usp      | 100 100 0 100 72 | 73 83 78                   |            |
| Enterotoxin SenB/TieB                   |senB     | 79 38 45 56 52 | 53 58 55                   |            |
| Alpha-hemolysin                         |hlyABD   | 53 0 27 0 60 | 28 43 35                   |            |
| Cytotoxic necrotizing factor 1          |cnt1     | 53 0 0 0 48 | 20 35 28                   |            |
| Cytolethal distending toxin             |cdtB     | 0 0 0 4 0 | 0 3 1                      |            |
| Shiga-like toxin                        |sbx      | 0 0 0 0 0 | 0 0 0                      |            |
| Heat-labile enterotoxin                 |elt      | 0 0 0 0 0 | 0 0 0                      |            |
| Heat-stable enterotoxin 1               |asta     | 0 0 0 0 0 | 0 0 0                      |            |
| Enterotoxin 1                           |setl     | 0 0 0 0 0 | 0 0 0                      |            |

Abbreviations: ST, sequence type; VF, virulence factor; CFA, colonization factor antigen; AAF, aggregative adhesion fimbria; SPATE, serine protease auto-transporters of Enterobacteriaceae; sat, secreted autotransporter toxin; AIDA, adhesin involved in diffuse adherence.

The median virulence score for all 80 isolates was 15 (range, 0–21). Virulence scores differed significantly among ST groups (Fig. 1). ST12 and ST73 isolates had high virulence scores, ranging from 17–20.

DISCUSSION

We hypothesized that we could define specific VFs of E. coli linked to bacterial movement from the urinary tract to the circulation. However, virulence properties as well as molecular epidemiological traits and antimicrobial resistance patterns showed no significant differences between blood and urine isolates from our cohort of UTI patients, suggesting that specific VFs of E. coli do not contribute to bacterial dissemination from the urinary tract to the circulation. However, specific isolates, such as ST131, carried more VF genes and exhibited higher antimicrobial resistance than the other isolates evaluated.

We classified isolates according to ST-fimH-OH serotype clonal groups using WGS. The ST131-fimH30-025:H4 type was the most prevalent and was highly resistant to several antibiotics, including β-lactams and fluoroquinolones. Among the 14 ST131-fimH30-025:H4 isolates, 12 produced CTX-M type ESBLs and carried variations in gyrA, parC, and parE. The next three most prevalent ST-fimH isolates were ST95-fimH27, ST69-fimH27, and ST1193-fimH64. ST131 is the predominant E. coli lineage among multidrug-resistant ExPEC isolates worldwide [14]. Most ST131 isolates are fluoroquinolone-resistant, many are co-resistant to aminoglycosides and cotrimoxazole, and a minority produce ESBLs, such as CTX-M enzymes [5, 14]. In our study, 78.9% of the ST131 isolates produced CTX-M ESBLs and were resistant to fluoroquinolones, and 52.6% of these were co-resistant to aminoglycosides and cotrimoxazole. After the
rapid expansion of ST131 *E. coli* strains, fluoroquinolone-resistant ST1193 isolates emerged [4]. ST1193 strains, derived from ST14, are commonly resistant to fluoroquinolones. *fimH*64 is a highly specific marker for ST1193, a clonal group that may be entirely fluoroquinolone-resistant [4]. Consistent herewith, all ST1193-*fimH*64 isolates in our study were resistant to fluoroquinolones.

Adhesins, including fimbriae and afimbrial adhesins, play a significant role in host cell colonization [7, 15]. We detected type I fimbriae, *E. coli* common pilus, hemorrhagic *E. coli* pilus, and *EaeH* in all isolates. P fimbriae were detected in 80% of the isolates. ExPEC can cause sepsis and infections under very low iron availability, as this pathotype has developed many strategies for obtaining iron [16]. The *sitABCD* system is a membrane pump system, and the ChuA transporter enables Fe uptake directly from extracellular heme. In addition, ExPEC have siderophores, such as salmochelin, yersiniabactin, and aerobactin, which are small molecules with high affinity for Fe ions that indirectly uptake Fe [17]. Yersiniabactin contributes to the pathogenicity of UPEC during urinary tract colonization [18, 19]. In our study, 98% isolates had yersiniabactin, the *sitABCD* system, and the chuA transporter. Aerobactin receptors are substantially more efficient at capturing Fe than enterobactin receptors [7]. In this study, 74% and 89% of the ST131 and ST1193 isolates, respectively, had the gene encoding aerobactin. An ExPEC salmochelin marker gene, *iroN*, was detected in 5% of the ST131 isolates, but in none of the ST1193 isolates.

Some of the most frequently detected toxin genes in ExPEC are *hly*A, *hly*D, *hly*F, *cdt*B, *tsh*, *sat*, *pic*, *vat*, and *ast*A [7]. *hly*F, *cdt*B, and *tsh* have been detected in NMEC strains [20]. While all isolates carried *hly*E in this study, alpha-hemolysins encoded by *hly*ABCD were detected in only 53% of ST131 and 27% of ST69 isolates. The *cnf1* gene was detected in 53% of the ST131 isolates. The presence of these genes in ST131 isolates suggests that they exhibit high virulence and toxicity compared with non-ST131 isolates. The *ibeA* protein recognizes surface receptors on brain capillary endothelial cells, allowing the pathogen to invade the nervous system and cause neonatal meningitis [21–23]. Therefore, *ibeA* is a representative VF gene in NMEC strains. In our study, three of each of ST357, ST372, and ST998 isolates (5%) carried *ibeA*. Major UTI pathogens, such as ST131 and ST1193, may not carry *ibeA* and therefore, do not cause meningitis in neonates.

ST131 isolates carried more VF genes, including *tsh* and *espC*, than non-ST131 isolates. The VF genes in ST131 isolates may play a role in pathogenesis. In a previous study, *tsh* was present in >50% of avian pathogenic *E. coli* isolates, 4.5% of UPEC isolates, and 11.5% of NMEC isolates [15]. In this study, all ST131 and ST1193 isolates among UTI-associated *E. coli* isolates carried *tsh*. Although the function of the temperature-sensitive hemagglutinin encoded by *tsh* in human infections is unclear, in *Bacteroides fragilis*, this protein contributes to abscess formation in intra-abdominal infections [24]. ST127 isolates can cause bacteremia in adults and are highly virulent in experimental models of invasive *E. coli* infection. Therefore, ST127 isolates should be monitored because of their greater pathogenic potential than more widely recognized clones, including ST73, ST95, and ST131 [25]. Two ST127 isolates were recovered from urine in this study and had high virulence scores of 20 and 17.

ST131 isolates reportedly had a higher virulence potential than other *E. coli* types in a murine sepsis model [5]. Similarly, in this study, ST131 isolates had higher virulence scores than ST1193, ST95, and ST69 isolates (P < 0.05). Shah, et al. [26] suggested a significant association between VFs and antimicrobial resistance in UPEC. Consistent herewith, we found that ST131 isolates of UTI patients had several VFs and a high resistance rate to several antibiotics.

Our study had some limitations, mainly related to the relatively small specimen size. Because of the limited number of *E. coli* bacteremia isolates reported, larger studies are needed to accurately determine the VF composition of these isolates in relation to their clonal characteristics. Further studies are needed to clarify the association between virulence and antibiotic resistance in
urosepsis-related *E. coli* strains. Second, WGS analysis and web-based assessment are subject to experimental error. Third, the association between VFs and disease severity could not be clarified in this study.

In conclusion, *E. coli* bacteremia isolates from UTI patients were analyzed for a broad range of VFs, molecular backgrounds, and antibiotic resistance genes using WGS. We found no STs and VFs associated with bacteremia in WGS data of *E. coli* isolated from UTI patients. ST131, a pandemic multidrug-resistant clone present in both blood and urine specimens, was the most frequent ST and carried more VF genes, especially *tsh* and *espC*, than non-ST131 isolates.

**ACKNOWLEDGEMENTS**

None.

**AUTHOR CONTRIBUTIONS**

Lee Y and Kim B designed the study; Kim J collected and identified clinical isolates and performed molecular studies; Lee Y, Kim B, and Kim J analyzed the data; Lee Y and Kim B wrote, edited, and reviewed the manuscript. All authors revised and accepted the final version of the manuscript.

**CONFLICTS OF INTEREST**

No potential conflicts of interest relevant to this article were reported.

**RESEARCH FUNDING**

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2019R1F1A1061400).

**ORCID**

Bongyoung Kim https://orcid.org/0000-0002-5029-6597
Jin-Hong Kim https://orcid.org/0000-0002-5369-0725
Yangsoo Lee https://orcid.org/0000-0003-3821-3741

**REFERENCES**

1. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;7:653-60.
2. Pitout JD. Extraintestinal pathogenic *Escherichia coli*: A combination of virulence with antibiotic resistance. Front Microbiol 2012;3:9.
3. Shaik S, Ranjan A, Tiwari SK, Hussain A, Nandanwar N, Kumar N, et al. Comparative genomic analysis of globally dominant ST131 clone with other epidemiologically successful extraintestinal pathogenic *Escherichia coli* (ExPEC) lineages. mBio 2017:8; e01596-17.
4. Tchesnokova VL, Rechkina E, Larson L, Ferrier K, Weaver JL, Schroeder DW, et al. Rapid and extensive expansion in the United States of a new multidrug-resistant *Escherichia coli* clonal group, sequence type 1193. Clin Infect Dis 2019;68:334-7.
5. Johnson JR, Porter SB, Zhanel G, Denamur E. Virulence of *Escherichia coli* clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012;80:1554-62.
6. Lee E and Lee Y. Prevalence of *Escherichia coli* carrying *psl* islands in bacteremia patients. Ann Lab Med 2018;38:271-3.
7. Sarowska J, Futoma-Koloch B, Jama-Kmieciec A, Frej-Madrzak M, Książczyk M, Bugia-Ploskonska G, et al. Virulence factors, prevalence and potential transmission of extraintestinal pathogenic *Escherichia coli* isolated from different sources: recent reports. Gut Pathog 2019;11:10.
8. La Combe B, Clermont O, Messika J, Eveillard M, Kouatchou A, Lasocki S, et al. Pneumonia-specific *Escherichia coli* with distinct phylogenetic and virulence profiles, France, 2012–2014. Emerg Infect Dis 2019;25:710-8.
9. Mora-Rillo M, Fernández-Romero N, Navarro-San Francisco C, Díez-Sebastián J, Romero-Gómez MP, Fernández FA, et al. Impact of virulence genes on sepsis severity and survival in *Escherichia coli* bacteremia. Virulence 2015;6:93-100.
10. Jaureguí F, Carbonnelle E, Bonacorsi S, Clec'h C, Casassus P, Bingen E, et al. Host and bacterial determinants of initial severity and outcome of *Escherichia coli* sepsis. Clin Microbiol Infect. 2007;13:854-62.
11. Cole BK, Ilikj M, McCloskey CB, Chavez-Bueno S. Antibiotic resistance and molecular characterization of bacteremia *Escherichia coli* isolates from newborns in the United States. PLoS One 2019;14:e0219352.
12. CLSI. Performance standards for antimicrobial susceptibility testing. 30th ed., CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute, 2020.
13. Liu B, Zheng D, Jin Q, Chen L, Yang J. VFDB 2019: a comparative pathogenic platform with an interactive web interface. Nucleic Acids Res 2019;47:D687-92.
14. Matsumura Y, Johnson JR, Yamamoto M, Nagao M, Tanaka M, Takakura S, et al. CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant *Escherichia coli* of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic. J Antimicrob Chemother 2015;70:1639-49.
15. Dhanji H, Doumith M, Rooney PJ, O’Leary MC, Loughrey AC, Hope R, et al. Molecular epidemiology of fluoroquinolone-resistant ST131 *Escherichia coli* producing CTX-M extended-spectrum beta-lactamasers in nursing homes in Belfast, UK. J Antimicrob Chemother 2011;66:297-303.
16. Antão EM, Wieler LH, Ewers C. Adhesive threads of extraintestinal pathogenic *Escherichia coli*. Gut Pathog 2009;1:22.
17. Gao Q, Wang X, Xu H, Xu Y, Ling J, Zhang D, et al. Roles of iron acquisition systems in virulence of extraintestinal pathogenic *Escherichia coli*: salmochelin and aerobactin contribute more to virulence than heme in a chicken infection model. BMC Microbiol 2012;12:143.
18. Mithke M and Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007;71:413-51.
19. Caza M, Lépine F, Dozois CM. Secretion, but not overall synthesis, of *vsaE*, *vaE*, and *vsaB* is required for virulence of *Escherichia coli* serotype O157:H7. Mol Microbiol 2003;49:710-3.
pathogenic *Escherichia coli*. Mol Microbiol 2011;80:266-82.

20. Johnson JR, Magistro G, Clabots C, Porter S, Manges A, Thuras P, et al. Contribution of yersiniabactin to the virulence of an *Escherichia coli* sequence type 69 (‘clonal group A’) cystitis isolate in murine models of urinary tract infection and sepsis. Microb Pathog 2018;120:128-31.

21. Mellata M, Johnson JR, Curtiss R, 3rd. *Escherichia coli* isolates from commercial chicken meat and eggs cause sepsis, meningitis and urinary tract infection in rodent models of human infections. Zoonoses Public Health 2018;65:103-13.

22. Bonacorsi S and Bingen E. Molecular epidemiology of *Escherichia coli* causing neonatal meningitis. Int J Med Microbiol 2005;295:373-81.

23. Zhao WD, Liu DX, Wei JY, Miao ZW, Zhang K, Su ZK, et al. Caspr1 is a host receptor for meningitis-causing *Escherichia coli*. Nat Commun 2018;9:2296.

24. Otto BR, van Dooren SJ, Dozois CM, Luirink J, Oudega B. *Escherichia coli* hemoglobin protease autotransporter contributes to synergistic abscess formation and heme-dependent growth of *Bacteroides fragilis*. Infect Immun 2002;70:5-10.

25. Alghoribi MF, Gibreel TM, Dodgson AR, Beatson SA, Upton M. *Galleria mellonella* infection model demonstrates high lethality of ST69 and ST127 uropathogenic *E. coli*. PLoS One 2014;9:e101547.

26. Shah C, Baral R, Bartaula B, Shrestha LB. Virulence factors of uropathogenic *Escherichia coli* (UPEC) and correlation with antimicrobial resistance. BMC Microbiol 2019;19:204.